NasdaqGS:GLUEBiotechs
Is Positive MRT-2359 Combo Data at ASCO GU 2026 Altering The Investment Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics recently reported updated, positive Phase 1/2 data showing that its investigational GSPT1 degrader MRT-2359, combined with enzalutamide, was well-tolerated in heavily pretreated metastatic castration-resistant prostate cancer patients, and the company now plans to move the regimen into Phase 2 development.
The ASCO GU 2026 presentation highlights Monte Rosa’s progress in applying its molecular glue degrader platform to a hard-to-treat, AR‑mutated prostate cancer...